Nuformix plc (LON:NFX – Get Free Report)’s share price dropped 15.1% on Tuesday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 9,097,313 shares traded hands during mid-day trading, a decline of 17% from the average daily volume of 10,972,615 shares. The stock had previously closed at GBX 0.05 ($0.00).
Nuformix Trading Up 4.0 %
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The business has a 50-day moving average price of GBX 0.05 and a two-hundred day moving average price of GBX 0.12. The firm has a market cap of £426,041.20, a PE ratio of -1.63 and a beta of 1.22.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- Best Stocks Under $10.00
- Why Aehr Test Systems Could Be a Hidden AI Semiconductor Winner
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Get Ahead of the January Effect With These 2 Fintech Stocks
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Stock Buybacks Outperform Dividends: Here’s the Key Advantage
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
